Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız:
http://hdl.handle.net/11452/34731
Tüm üstveri kaydı
Dublin Core Alanı | Değer | Dil |
---|---|---|
dc.date.accessioned | 2023-11-01T08:29:44Z | - |
dc.date.available | 2023-11-01T08:29:44Z | - |
dc.date.issued | 2007-03 | - |
dc.identifier.citation | Filiz, G. vd. (2007). "The relationship between MIB-1 proliferative activity and mitotic index in gastrointestinal stromal tumors". Hepato-Gastroenterology, 54(74), 438-441. | en_US |
dc.identifier.issn | 0172-6390 | - |
dc.identifier.uri | http://hdl.handle.net/11452/34731 | - |
dc.description.abstract | Background/Aims: Gastrointestinal stromal tumors (GIST) are mesenchymal tumors originating from the gastrointestinal canal wall. Although a number of studies are performed concerning prognostic factors, no indicators of recurrence or metastasis could be established. In this study we assessed the prognostic value of MIB-1 proliferative index (PI) in GIST, and whether there was a relationship to any other clinicopathological findings. Methodology: In the study 37 patients with GIST diagnosis were included. The cases were classified as low, intermediate, and high risk groups according to tumor size and mitotic activity. The average PI of 10% in high risk group was set as the cut-off value. Results: Of all the cases, those with a MIB-1 PI over the cut-off value had a significantly shorter survival (Log-rank test, p < 0.05). Likewise cases with small bowel tumors with. a MIB-1 PI over the cut-off value had a significantly shorter survival (Log-rank test, p < 0.05). A statistically significant negative correlation was found between presence of necrosis and survival using McPearson correlation test (p < 0.01). Conclusions: MIB-1 PI and presence of necrosis are possible indicators of prognosis especially in GIST cases of the small bowel. | en_US |
dc.language.iso | en | en_US |
dc.publisher | H.G.E. Update Medical Publishing | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Gastroenterology & hepatology | en_US |
dc.subject | Surgery | en_US |
dc.subject | Gastrointestinal stromal tumor | en_US |
dc.subject | Proliferative indexprognosis | en_US |
dc.subject | Mib-1 | en_US |
dc.subject | Prognostic value | en_US |
dc.subject | Dna-ploidy | en_US |
dc.subject | Immunoreactivity | en_US |
dc.subject | Cell | en_US |
dc.subject | Expression | en_US |
dc.subject | Stomach | en_US |
dc.subject | Ki-67 | en_US |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Biopsy | en_US |
dc.subject.mesh | Cell division | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Gastrointestinal stromal tumors | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Immunoenzyme techniques | en_US |
dc.subject.mesh | Intestinal mucosa | en_US |
dc.subject.mesh | Ki-67 antigen | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Mitotic index | en_US |
dc.subject.mesh | Prognosis | en_US |
dc.subject.mesh | Survival analysis | en_US |
dc.title | The relationship between MIB-1 proliferative activity and mitotic index in gastrointestinal stromal tumors | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000246271800027 | tr_TR |
dc.identifier.scopus | 2-s2.0-34248137859 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Cerrahi Patoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı. | tr_TR |
dc.identifier.startpage | 438 | tr_TR |
dc.identifier.endpage | 441 | tr_TR |
dc.identifier.volume | 54 | tr_TR |
dc.identifier.issue | 74 | tr_TR |
dc.relation.journal | Hepato-Gastroenterology | en_US |
dc.contributor.buuauthor | Filiz, Gülaydan | - |
dc.contributor.buuauthor | Yalçınkaya, Ülviye | - |
dc.contributor.buuauthor | Gürel, Selim | - |
dc.contributor.buuauthor | Yerci, Ömer | - |
dc.contributor.buuauthor | Memik, Faruk | - |
dc.contributor.researcherid | EVQ-8652-2022 | tr_TR |
dc.contributor.researcherid | AAH-8924-2021 | tr_TR |
dc.contributor.researcherid | HLH-8209-2023 | tr_TR |
dc.contributor.researcherid | EIS-5114-2022 | tr_TR |
dc.contributor.researcherid | DGO-4135-2022 | tr_TR |
dc.identifier.pubmed | 17523292 | tr_TR |
dc.subject.wos | Gastroenterology & hepatology | en_US |
dc.subject.wos | Surgery | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q3 (Surgery) | en_US |
dc.wos.quartile | Q4 (Gastroenterology & hepatology) | en_US |
dc.contributor.scopusid | 6602693514 | tr_TR |
dc.contributor.scopusid | 6508300295 | tr_TR |
dc.contributor.scopusid | 7003706434 | tr_TR |
dc.contributor.scopusid | 6603810549 | tr_TR |
dc.contributor.scopusid | 6701813462 | tr_TR |
dc.subject.scopus | Gastrointestinal Stromal Tumors; Imatinib; Cancer | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Clinical article | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Gastrointestinal stromal tumor | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Mitosis index | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Risk factor | en_US |
dc.subject.emtree | Survival | en_US |
dc.subject.emtree | Tumor localization | en_US |
dc.subject.emtree | Tumor volume | en_US |
dc.subject.emtree | Ki 67 antigen | en_US |
Koleksiyonlarda Görünür: | PubMed Scopus Web of Science |
Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.